WO2026041980 - METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
National phase entry is expected:
Publication Number
WO/2026/041980
Publication Date
26.02.2026
International Application No.
PCT/IB2025/058322
International Filing Date
18.08.2025
Title **
[English]
METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
[French]
MÉTHODES DE TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES (NSCLC)
Applicants **
JANSSEN BIOTECH, INC.
Inventors
BAUML, Joshua
CHIODA, Marc
Priority Data
63/684,832
19.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3739 | |
| EPO | Filing, Examination, Granting | 17175 | |
| Japan | Filing, Examination, Granting | 2339 | |
| South Korea | Filing, Examination, Granting | 2442 | |
| USA | Filing, Examination, Granting | 6890 |
Total:
32,585
Contact Us
Abstract[English]
Provided are methods relating to subjects that are receiving lazertinib in a dosage of 240 mg/day, in combination with a dosage of amivantamab, in order to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations in the subject.[French]
L'invention concerne des méthodes se rapportant à des sujets qui reçoivent du lazertinib à une dose de 240 mg/jour, en combinaison avec un dosage d'amivantamab, afin de traiter un cancer du poumon non à petites cellules localement avancé ou métastatique (NSCLC) avec des délétions de l'exon 19 du récepteur du facteur de croissance épidermique (EGFR) ou des mutations de substitution L858R de l'exon 21 chez le sujet.